Until now, there have been several clinical trials and reports in which a CB1R antagonist has been administered as treatment for obesity or metabolic risk factors.43–45 The two most notable clinical trials are the ADAGIO-Lipids Trial and the Rimonabant in Obesity (RIO)-Europe study. Here, CNR1 is linked to Obesity.